Prascend

Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) (Equine Cushing’s Disease).

Description

PDF Product Sheet PRASCEND

Composition                              

Each tablet contains:

Pergolide

(as pergolyde mesylate 1.31mg)

 

1.0 mg
Characteristics

Pergolide is a synthetic ergot derivative and is a potent, long-acting dopamine receptor agonist. Both in vitro and in vivo pharmacological studies have demonstrated the activity of Pergolide as a selective dopamine agonist with little or no effect on norepinephrine, epinephrine or serotonin pathways at therapeutic doses. As with other dopamine agonists, Pergolide inhibits the release of prolactin. In horses with Pituitary Pars Intermedia Dysfunction (PPID) Pergolide exerts its therapeutic effect by stimulating dopamine receptors. Further, in horses with PPID, Pergolide has been shown to decrease the plasma levels of ACTH, MSH and other pro-opiomelanocortin peptides.